Novartis on track to buy Cytokinetics, insider says
Swiss drugmaker could gain access to an experimental treatment for hypertrophic cardiomyopathy
09 January 2024 - 15:47
by Agency Staff
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Bengaluru/New York/Zurich — Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well more than $10bn, a source familiar with the matter said on Monday.
Novartis is poised to prevail in the auction for Cytokinetics, ahead of other bidders that include AstraZeneca and Johnson & Johnson, according to the source.
A deal could be announced as early as this week, the source said, helping Novartis gain access to Cytokinetics’ experimental treatment, aficamten, for hypertrophic cardiomyopathy (HCM), an inherited chronic heart disease that can cause cardiac arrest.
Spokespersons for Cytokinetics and Novartis said the companies do not comment on mergers and acquisitions speculation.
Shares of Cytokinetics rose more than 16% on Monday after the Wall Street Journal first reported on Novartis’ lead.
Novartis shares were broadly unchanged in early trading in Switzerland on Tuesday.
Vontobel pharmaceuticals analyst Stefan Schneider said a deal makes sense for Novartis, with Cytokinetics active in the cardiovascular field, one of the Swiss company’s five main therapeutic areas.
Access to Cytokinetics products would help Novartis offset the expected loss of US exclusivity of Entresto, its key drug in this field, he added.
“Novartis would probably have to pay a significant premium to the current share price,” Schneider said.
“Novartis could easily manage a takeover in the low double-digit billion dollar range and would also have further financial leeway for acquisitions afterwards,” he added.
In late December, Cytokinetics’ shares jumped more than 82% after aficamten met the main goal of a keenly awaited late-stage study, putting it on track to compete with a rival treatment from Bristol Myers Squibb.
Shares of Cytokinetics with a market capitalisation of more than $9bn, at Friday’s closing price, have more than tripled in value since October 31, when reports of the company attracting takeover interests first surfaced.
HCM is the most common inherited cardiovascular disorder, with about 280,000 patients in the US now, including two-thirds with obstructive HCM and the rest with non-obstructive HCM, the company estimates.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Novartis on track to buy Cytokinetics, insider says
Swiss drugmaker could gain access to an experimental treatment for hypertrophic cardiomyopathy
Bengaluru/New York/Zurich — Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well more than $10bn, a source familiar with the matter said on Monday.
Novartis is poised to prevail in the auction for Cytokinetics, ahead of other bidders that include AstraZeneca and Johnson & Johnson, according to the source.
A deal could be announced as early as this week, the source said, helping Novartis gain access to Cytokinetics’ experimental treatment, aficamten, for hypertrophic cardiomyopathy (HCM), an inherited chronic heart disease that can cause cardiac arrest.
Spokespersons for Cytokinetics and Novartis said the companies do not comment on mergers and acquisitions speculation.
Shares of Cytokinetics rose more than 16% on Monday after the Wall Street Journal first reported on Novartis’ lead.
Novartis shares were broadly unchanged in early trading in Switzerland on Tuesday.
Vontobel pharmaceuticals analyst Stefan Schneider said a deal makes sense for Novartis, with Cytokinetics active in the cardiovascular field, one of the Swiss company’s five main therapeutic areas.
Access to Cytokinetics products would help Novartis offset the expected loss of US exclusivity of Entresto, its key drug in this field, he added.
“Novartis would probably have to pay a significant premium to the current share price,” Schneider said.
“Novartis could easily manage a takeover in the low double-digit billion dollar range and would also have further financial leeway for acquisitions afterwards,” he added.
In late December, Cytokinetics’ shares jumped more than 82% after aficamten met the main goal of a keenly awaited late-stage study, putting it on track to compete with a rival treatment from Bristol Myers Squibb.
Shares of Cytokinetics with a market capitalisation of more than $9bn, at Friday’s closing price, have more than tripled in value since October 31, when reports of the company attracting takeover interests first surfaced.
HCM is the most common inherited cardiovascular disorder, with about 280,000 patients in the US now, including two-thirds with obstructive HCM and the rest with non-obstructive HCM, the company estimates.
Reuters
Bayer’s drug to relieve menopause-related hot flushes succeeds in late-stage trial
Biotech M&A spree buoys healthcare dealmakers before US conference
Adherence to Wegovy at 40% a year later, but still much higher than for older drugs
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Aspen acquires Sandoz subsidiary as it seeks to expand in China
Big Pharma turns to AI to cut costs and development time
US drugmakers want court to help them avoid negotiating prices with Medicare
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.